Key result
Blockade of sarcolemmal TRPV2 accumulation using the NT domain or tranilast prevented ventricular dilation and fibrosis, ameliorated contractile dysfunction, and improved survival in DCM animal models.
Why the study?
Does blockade of TRPV2 inhibit progression of dilated cardiomyopathy in animal models?
Does blockade of TRPV2 inhibit progression of dilated cardiomyopathy in animal models?
Blockade of sarcolemmal TRPV2 accumulation prevents ventricular dilation and improves survival in animal models of dilated cardiomyopathy, highlighting a potential therapeutic target for advanced heart failure.
No takes yet. Share an insight, caveat, or question.
TRPV2 blockade may attenuate DCM progression in models; leaves open clinical translation pending prospective trials.
Iwata et al. (2013) studied Dilated cardiomyopathy (DCM). TRPV2 blockade (NT domain over-expression or tranilast) was evaluated on DCM progression (ventricular dilation, fibrosis, contractile dysfunction, survival). Blockade of sarcolemmal TRPV2 accumulation using the NT domain or tranilast prevented ventricular dilation and fibrosis, ameliorated contractile dysfunction, and improved survival in DCM animal models.